WHO ICTRP trial
A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric…
NL-OMON41557 · Overview of Medical Research in the Netherlands (NL-OMON) · Not Recruiting
Key facts
| Trial ID | NL-OMON41557 |
|---|---|
| Public title | A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin |
| Scientific title | A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects with Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin - CD-ON-CAT8015-1036 |
| Primary sponsor | MedImmune, LLC |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | 2 |
| Countries | France;Germany;Italy;Netherlands ;Poland;Spain;United Kingdom |
| Conditions | Pediatric Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma;10024324;Pediatric Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma |
| Interventions | Subjects will receive a cycle of moxetumomab pasudotox every 21 days until PD or until they meet a study withdrawal criteria. Each cycle will consist of a total of 6 doses of moxetumomab pasudotox at 40µg/kg given every other day of a… |
| Registration date | Aug 19, 2015 |
| Target size | 4 |
| Secondary IDs | 2012-003101-10;IND 100372 en NTC0227108;NL43470.078.14 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: